Earnings News
FONT-SIZE Plus   Neg
Share SHARE

AstraZeneca Q1 Pre-tax Profit Down; Cuts 2012 Core EPS View; CEO To Retire

RELATED NEWS
Trade AZN now with 

AstraZeneca Plc (AZN: Quote,AZN.L) reported first quarter pre-tax profit of $2.05 billion versus $3.29 billion last year. Earnings per $0.25 Ordinary share were down to $1.28 from $2.07 a year ago.

Core earnings per share were $1.81 in the first quarter, down 19 percent from a year ago, which benefited by $0.46 from two one-off gains. Excluding these gains, Core EPS would have increased by 2 percent compared with last year.

On average, three analysts polled by Thomson Reuters expected the company to report earnings of $1.78 per share. Analysts' estimates typically exclude special items.

Revenue declined to $7.35 billion from $8.29 billion last year. Analysts estimated revenues of $7.85 billion.

Loss of exclusivity on several key brands accounted for 8 percentage points of the revenue decline, which included the recognition of a $223 million returns reserve against US trade inventories of Seroquel IR following generic launches at the end of March 2012, the company said.

AstraZeneca anticipates a rebound in the remaining three quarters, but achieving double-digit growth for the full year may be a challenge.

The company lowered its Core EPS target for the full year 2012 to the range of $5.85 to $6.15 from $6.00 to $6.30. AstraZeneca now expects the decline in revenue for the full year will be in the range of the low to mid-teens in constant currency terms. Analysts expect the company to earn $6.14 per share, on revenues of $30.01 billion.

Earlier, Astrazeneca anticipated a constant currency revenue decline for 2012 in the low double-digit range.

Separately, AstraZeneca announced that Chief Executive Officer and Board member, David Brennan has decided to retire. David Brennan will retire from AstraZeneca and relinquish his Board responsibilities on 1 June 2012.

Following David's decision, the Board named Executive Director and Chief Financial Officer Simon Lowth as interim Chief Executive Officer from 1 June 2012 until a permanent successor is in place. Julie Brown, Vice President Group Finance, will become interim Chief Financial Officer on the same date.

Register
To receive FREE breaking news email alerts for AstraZeneca PLC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.